The use of selective CB.sub.1 receptor antagonistic compounds for treating
and/or inhibiting CB.sub.1 receptor related diseases in juvenile patients
(pediatric treatment), e.g. in particular obesity in juvenile patients,
and/or for the treatment and/or inhibition of drug induced obesity in
juvenile as well as in adolescent patients, and for the manufacture of
pharmaceutical compositions for such purposes.
